BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22591444)

  • 1. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults.
    Badiali M; Gleize V; Paris S; Moi L; Elhouadani S; Arcella A; Morace R; Antonelli M; Buttarelli FR; Figarella-Branger D; Kim YH; Ohgaki H; Mokhtari K; Sanson M; Giangaspero F
    Brain Pathol; 2012 Nov; 22(6):841-7. PubMed ID: 22591444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.
    Kim YH; Nonoguchi N; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Mariani L; Giangaspero F; Tanaka Y; Nakazato Y; Vital A; Mittelbronn M; Perry A; Ohgaki H
    Brain Pathol; 2012 Nov; 22(6):834-40. PubMed ID: 22568401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
    Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas.
    Appay R; Fina F; Macagno N; Padovani L; Colin C; Barets D; Ordioni J; Scavarda D; Giangaspero F; Badiali M; Korshunov A; M Pfister S; T W Jones D; Figarella-Branger D
    Mod Pathol; 2018 Oct; 31(10):1490-1501. PubMed ID: 29802359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
    Tian Y; Rich BE; Vena N; Craig JM; Macconaill LE; Rajaram V; Goldman S; Taha H; Mahmoud M; Ozek M; Sav A; Longtine JA; Lindeman NI; Garraway LA; Ligon AH; Stiles CD; Santagata S; Chan JA; Kieran MW; Ligon KL
    J Mol Diagn; 2011 Nov; 13(6):669-77. PubMed ID: 21884820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.
    Kumar A; Pathak P; Purkait S; Faruq M; Jha P; Mallick S; Suri V; Sharma MC; Suri A; Sarkar C
    Cancer Genet; 2015 Mar; 208(3):91-5. PubMed ID: 25794445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.
    Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST
    J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.
    Kurani H; Gurav M; Shetty O; Chinnaswamy G; Moiyadi A; Gupta T; Jalali R; Epari S
    Childs Nerv Syst; 2019 Sep; 35(9):1525-1536. PubMed ID: 31321520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas.
    Cruz GR; Dias Oliveira I; Moraes L; Del Giudice Paniago M; de Seixas Alves MT; Capellano AM; Saba-Silva N; Cavalheiro S; Cerutti JM; Toledo SR
    J Neurooncol; 2014 Apr; 117(2):235-42. PubMed ID: 24532263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
    Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
    Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
    Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
    Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.
    Lin A; Rodriguez FJ; Karajannis MA; Williams SC; Legault G; Zagzag D; Burger PC; Allen JC; Eberhart CG; Bar EE
    J Neuropathol Exp Neurol; 2012 Jan; 71(1):66-72. PubMed ID: 22157620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.